Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: analysis of MagnetisMM-3

被引：0
|
作者：
Touzeau, Cyrille [1 ]
Weisel, Katja [2 ]
Bahlis, Nizar [3 ]
Quach, Hang [4 ]
Hamilton, Finn [5 ]
Wang, Shen-wu [5 ]
Leip, Eric [5 ]
Viqueira, Andrea [6 ]
O'Brien, Thomas [5 ]
Rodriguez-Otero, Paula [7 ]
机构：
[1] CHU Nantes, Nantes, France
[2] Univ Canc Ctr Hamburg, Hamburg, Germany
[3] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[4] Univ Melbourne, Vincents Hosp Melbourne, Parkville, Vic, Australia
[5] Pfizer Inc, New York, NY USA
[6] Pfizer SLU, Madrid, Spain
[7] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-087
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [31] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
    Lesokhin, Alexander M.
    Arnulf, Bertrand
    Niesvizky, Ruben
    Mohty, Mohamad
    Bahlis, Nizar J.
    Tomasson, Michael H.
    Rodriguez-Otero, Paula
    Quach, Hang
    Raje, Noopur S.
    Iida, Shinsuke
    Raab, Marc-Steffen
    Czibere, Akos
    Sullivan, Sharon
    Leip, Eric
    Viqueira, Andrea
    Leleu, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol
    Bahlis, Nizar J.
    Trudel, Suzanne
    Maisel, Christopher
    Lee, Lisa X.
    Monge, Jorge
    Prada, Claudia Paba
    Larson, Sarah M.
    Koehne, Guenther
    Jethava, Yogesh
    Ma, Wei Dong
    De Nicolo, Cristina
    Perez-Cruz, Isabel
    BLOOD, 2023, 142
  • [33] MINIMAL RESIDUAL DISEASE NEGATIVITY AS A MEASURE OF RESPONSE TO CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Aronson, Elizabeth
    Madduri, Deepu
    Suarez, Jacklyn
    Florendo, Erika
    Pacaud, Lida
    Steinbach, Mary
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [34] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, A. Eli
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur S.
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos Gabor
    Viqueira, Andrea
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms intriple-class refractory multiple myeloma (vol 20, pg 1175, 2024)
    Costa, Luciano J.
    LeBlanc, Thomas W.
    Tesch, Hans
    Sonneveld, Pieter
    Kyle, Ryan P.
    Sinyavska, Liliya
    Hlavacek, Patrick
    Meche, Aster
    Ren, Jinma
    Schepart, Alex
    Aydin, Didem
    Nador, Guido
    DiBonaventura, Marco daCosta
    FUTURE ONCOLOGY, 2024,
  • [36] MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
    Grosicki, Sebastian
    Crafoord, Jacob
    Koh, Youngil
    White, Darrel
    Mellqvist, Ulf-Henrik
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Pruchniewski, Lukasz
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies
    Elmeliegy, Mohamed
    Lon, Hoi Kei
    Wang, Diane
    Ma, Wei An
    King, Lindsay
    Viqueira, Andrea
    Czibere, Akos
    BLOOD, 2023, 142
  • [38] Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
    Mutlu, Yasa Gul
    Kaya, Sureyya Yigit
    Maral, Senem
    Melek, Elif
    Baslar, Zafer
    Kaynar, Leylagul
    Sevindik, Omur Gokmen
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
    Paiva, Bruno
    Cedena, Teresa
    Puig, Noemi
    Cordon, Lourdes
    Martinez-Lopez, Joaquin
    Ocio, Enrique M.
    Hernandez, Miguel T.
    Isabel Teruel, Ana
    Gironella, Mercedes
    Asuncion Echeveste, M.
    Rosinol, Laura
    Martinez, Rafael
    Oriol, Albert
    Martin, Jesus
    Gutierrez, Norma C.
    Belen Vidriales, Maria
    Blade, Joan
    Jose Lahuerta, Juan
    Mateos, Maria-Victoria
    San Miguel, Jesus
    BLOOD, 2015, 126 (23)
  • [40] Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: post-hoc analysis from MagnetisMM-3
    Leleu, Xavier
    Bahlis, Nizar
    Rodriguez-Otero, Paula
    Quach, Hang
    Touzeau, Cyrille
    Depaus, Julien
    Iida, Shinsuke
    Haenel, Mathias
    Wrobel, Tomasz
    Leip, Eric
    Conte, Umberto
    Sullivan, Sharon
    Viqueira, Andrea
    Lesokhin, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S194 - S194
12345